Mary Anne Heino Sells 26,066 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director now owns 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mary Anne Heino also recently made the following trade(s):

• On Thursday, March 13th, Mary Anne Heino sold 2 shares of Lantheus stock. The shares were sold at an average price of $100.13, for a total transaction of $200.26.

Lantheus Stock Performance

Shares of LNTH stock traded up $0.79 on Friday, hitting $81.12. 326,874 shares of the company's stock traded hands, compared to its average volume of 997,666. The stock has a market capitalization of $5.61 billion, a price-to-earnings ratio of 13.49 and a beta of 0.23. The company's fifty day simple moving average is $90.58 and its 200 day simple moving average is $91.66. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Lantheus's revenue for the quarter was up .8% on a year-over-year basis. During the same period last year, the firm earned $1.69 earnings per share. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

Large investors have recently added to or reduced their stakes in the company. Kestra Investment Management LLC purchased a new stake in shares of Lantheus during the fourth quarter worth about $27,000. Summit Securities Group LLC bought a new position in Lantheus during the 4th quarter valued at approximately $37,000. Signaturefd LLC lifted its holdings in Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after buying an additional 116 shares during the period. Quarry LP grew its position in shares of Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock worth $48,000 after buying an additional 470 shares during the last quarter. Finally, Hughes Financial Services LLC purchased a new position in shares of Lantheus during the first quarter valued at approximately $81,000. Institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

LNTH has been the topic of a number of research analyst reports. B. Riley decreased their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Truist Financial dropped their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $132.67.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.